Slide 1: Q2 2026 Financial Results and Business Highlights
Q2 2026 Financial Results and Business Highlights August 6, 2026 CONFIDENTIAL: FOR INTERNAL USE ONLY
Slide 2: Disclaimers
Disclaimers FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements about, among other things, Verastem Oncology’s (the “Company”) programs and product candidates, strategy, future plans and prospects, including statements related to the approval and commercialization of AVM
Slide 3: Q2 2026 Call Agenda
Q2 2026 Call AgendaAgenda Introduction Opening & AVMAPKI® FAKZYNJA® Q2 Financial Closing Remarks CO-PACK Update Performance JULISSA VIANA DAN PATERSON DAN LYONS DAN CALKINS SVP, Corporate President and Chief Chief Commercial Chief Financial Communications, Executive Officer Officer Officer Investor
Slide 4: Opening Remarks
Opening Remarks DAN PATERSON President & CEO 4
Slide 5: Key Takeaways for Q2 2026
Key Takeaways for Q2 2026 Meaningful Co-Pack Rebound & Momentum, Impressive Execution Across VS-7375 Pipeline Program Q2 FINANCIAL AVMAPKI FAKZYNJA VS-7375 PERFORMANCE CO-PACK PROGRESS • Strong quarter-over-quarter • Q2 $25.1M net product • Dosed first patient in all AVMAPKI FAKZYNJA CO- revenue thr
Slide 6: AVMAPKI FAKZYNJA CO-PACK Commercial Performance
AVMAPKI® FAKZYNJA® CO-PACK Commercial Performance DAN LYONS Chief Commercial Officer 6
Slide 7: AVMAPKI FAKZYNJA CO-PACK Steady Revenue Growth Since Launch
AVMAPKI FAKZYNJA CO-PACK Steady Revenue Growth Since Launch $25.1M in Net Product Revenue in Q2’26 $25.1M Achieved ~$74.5M in AVMAPKI FAKZYNJA CO-PACK $18.7M Net Product Revenue Since Launch in May 2025* $17.5M $11.2M Q3’25 Q4’25 Q1’26 Q2’26 NET PRODUCT REVENUE* Please see the full Prescribing Infor
Slide 8: AVMAPKI FAKZYNJA CO-PACK: Focused Execution will Drive Sustained Growth
AVMAPKI FAKZYNJA CO-PACK: Focused Execution will Drive Sustained Growth Priorities Q2 2026 Progress Consistent Consistent level of new patient starts New Patient throughout second quarter Starts Increasing evidence of repeat prescribing Use at Greater depth of prescribing among First or Next e
Slide 9: Q2 2026 Financial Update
Q2 2026 Financial Update DAN CALKINS Chief Financial Officer 9
Slide 10: Q2 2026 Financial Highlights
Q2 2026 Financial Highlights Proforma cash of $201.4M with Oberland and COPIKTRA sales milestone, combined with expected product revenue and future tranche from Oberland facility, expected to extend cash runway into 2H 2027 Financial Summary Three Months ($ in millions) Ended June 30, 2026 Net Produ
Slide 11: Closing Remarks
Closing Remarks DAN PATERSON President & CEO 11
Slide 12: Verastem Oncology 2H Outlook
Verastem Oncology 2H Outlook 1H 2026 Highlights Key Drivers for 2H 2026 Meaningful AVMAPKI FAKZYNJA CO-PACK • Continued execution on AVMAPKI momentum going into 2H FAKZYNJA CO-PACK commercialization Delivered strong Q2 performance • On track to provide update on VS-7375 in October 2026 Impress
Slide 13: Q&A
Q&A Dan Paterson Michael Kauffman, Dan Lyons Dan Calkins Julissa Viana President and Chief MD, PhD Chief Commercial Officer Chief Financial Officer SVP, Corporate Communications, Executive Officer President of Development Investor Relations and Patient Advocacy 13